Danish pharma giant Novo Nordisk has pledged support for India's National Sickle Cell Anaemia Elimination Mission, targeting 2047. India has 1.5–2 million patients, the second-highest globally. The company is advancing Phase 3 trials for a treatment and working with Indian regulators for early approval, while supporting diagnosis and awareness initiatives.